Solid Biosciences Inc. (NASDAQ: SLDB) saw its shares climb 14% after revealing an oversubscribed $240 million private placement with institutional investors. The life sciences company, known for developing precision genetic medicines targeting neuromuscular and cardiac diseases, secured significant backing from both existing and new investors.
Details of the Private Placement
The company entered into a securities purchase agreement with a select group of institutional accredited investors. Under the terms of the agreement, Solid Biosciences will sell 14,973,257 shares of common stock at $5.61 per share. Additionally, the company is offering pre-funded warrants to purchase up to 27,807,482 shares at $5.609 per warrant. These pre-funded warrants, which carry an exercise price of $0.001 per share, are exercisable immediately until fully exercised.
The transaction, expected to close on or around March 9, 2026, is subject to customary closing conditions. Solid Biosciences emphasized that the private placement adheres to Nasdaq rules, including the “Minimum Price” requirement.
Key Investors and Placement Agents
The private placement attracted a strong lineup of institutional investors, including Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, Invus, Vestal Point Capital, Janus Henderson Investors, and Deep Track Capital. This robust participation highlights confidence in Solid Biosciences’ pipeline and strategic direction.
Leading the financing efforts, Leerink Partners and Citigroup are serving as joint lead placement agents, with Cantor acting as co-lead placement agent. Truist and H.C. Wainwright & Co. are also contributing as co-placement agents.
Use of Proceeds
Solid Biosciences plans to allocate the net proceeds from the private placement to several key areas. These include advancing its ongoing pipeline development programs, supporting business development activities, and covering working capital and other general corporate purposes. The $240 million transaction amount is calculated before deducting placement agent fees and offering expenses.
To find out more about Solid Biosciences please visit www.solidbio.com.
The post Solid Biosciences Shares Surge 14% Following $240 Million Private Placement Announcement appeared first on PRISM MarketView.
